Document Classification

Section Type: RESULTS

Text: Fasting glucose increased in the tesamorelin group at 2 weeks (mean change, 9 mg/dL [95 % CI, 5-13 mg/dL] vs 2 mg/dL [95 % CI, -3 to 8 mg/dL] in the placebo group ; treatment effect, 7 mg/dL [95 % CI, 1-14 mg/dL] ; P =. 03), but changes at 6 months in fasting glucose (mean change, 4 mg/dL [95 % CI, -2 to 10 mg/dL] with tesamorelin vs 2 mg/dL [95 % CI, -4 to 7 mg/dL] with placebo ; treatment effect, 2 mg/dL [95 % CI, -6 to 10 mg/dL] ; P =. 72 overall across time points) and 2-hour glucose (mean change, -1 mg/dL [95 % CI, -18 to 15 mg/dL] vs -8 mg/dL [95 % CI, -24 to 8 mg/dL], respectively ; treatment effect, 7 mg/dL [95 % CI, -16 to 29 mg/dL] ; P =. 53 overall across time points) were not significant.